Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07266805 · ClinicalTrials.gov registry record · Phase 3
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
A Phase 3 study of Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH), sponsored by Pharvaris Netherlands B.V..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
- 7
- Study locations
NCT07266805 is a Phase 3 study of Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) that is actively recruiting participants, run by Pharvaris Netherlands B.V.. The registered enrollment target is 32 participants. The trial reports 7 study locations across 3 states.
The verdict
NCT07266805, a Phase 3 study of Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH), is actively recruiting participants, sponsored by Pharvaris Netherlands B.V..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant IR capsule for on-demand treatment of angioedema attacks in adult participants aged ≥ 18 years with AAE-C1INH.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Deucrictibant
Study Locations (7)
Other
- Study Site - Edmonton
- Study Site - Cambridge
- Study Site - Leicester
- Study Site - London
- Study Site - Plymouth
California
- Study Site - Walnut Creek
Missouri
- Study Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07266805
The ClinicalTrials.gov registry entry for NCT07266805 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharvaris Netherlands B.V., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07266805 reports 7 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT07266805 about?
NCT07266805 is a clinical study titled "Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency". This is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant IR capsule for on-demand treatment of angioe...
What is the current status of trial NCT07266805?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2025-10-16. Estimated completion is 2027-06.
What conditions does trial NCT07266805 study?
This clinical trial studies the following conditions: Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH).
What interventions are being tested in trial NCT07266805?
The interventions under investigation include: Placebo (DRUG), Deucrictibant (DRUG).
Who is sponsoring clinical trial NCT07266805?
This trial is sponsored by Pharvaris Netherlands B.V., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07266805 being conducted?
This trial has 7 study locations across California, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.